The Ambulatory Medical Assistance (AMA) programme during active‐phase treatment in patients with haematological malignancies: A cost‐effectiveness analysis

Anne‐sophie Michallet (), Stephanie Malartre, Elodie Vignaud, Alexiane Bocquet, Pascale Sontag, Christelle Galvez, Jean‐yves Blay (), Pierre Heudel, Alexandre Vimont (), Martin Blachier, Marie Ferrua, Etienne Minvielle () and Olivier Mir
Additional contact information
Anne‐sophie Michallet: Centre Léon Bérard [Lyon]
Stephanie Malartre: Centre Léon Bérard [Lyon]
Elodie Vignaud: Centre Léon Bérard [Lyon]
Alexiane Bocquet: Centre Léon Bérard [Lyon]
Pascale Sontag: Centre Léon Bérard [Lyon]
Christelle Galvez: Centre Léon Bérard [Lyon]
Jean‐yves Blay: Centre Léon Bérard [Lyon]
Pierre Heudel: Centre Léon Bérard [Lyon]
Alexandre Vimont: Public Health Expertise [Paris, France]
Martin Blachier: Public Health Expertise [Paris, France]
Marie Ferrua: DIOPP - Département interdisciplinaire d’organisation des parcours patients [Gustave Roussy] - IGR - Institut Gustave Roussy
Etienne Minvielle: DIOPP - Département interdisciplinaire d’organisation des parcours patients [Gustave Roussy] - IGR - Institut Gustave Roussy, CRG I3 - Centre de Recherche en Gestion I3 - X - École polytechnique - IP Paris - Institut Polytechnique de Paris - I3 - Institut interdisciplinaire de l’innovation - CNRS - Centre National de la Recherche Scientifique
Olivier Mir: IGR - Institut Gustave Roussy

Post-Print from HAL

Abstract: Context:The need for patient navigator is growing, and there is a lack of cost evaluation, especially during survivorship.Objective:The objective of this study is to evaluate the cost-effectiveness of an Ambulatory Medical Assistance (AMA) programme in patients with haematological malignancies (HM).Design:A cost-effectiveness analysis of the AMA programme was performed compared to a simulated control arm.Setting:An interventional, single-arm and prospective study was conducted in a French reference haematology–oncology centre between 2016 and 2020.Participants:Adult patients were enrolled with histologically documented malignant haematology, during their active therapy phase, and treated either by intravenous chemotherapy or oral therapy.Methods:An extrapolation of the effectiveness was derived from a similar nurse monitoring programme (CAPRI study). Cost effectiveness of the programme was evaluated through adverse events of Grade 3 or 4 avoided in different populations.Results:Included patient (n=797) from the AMA programme were followed during125 days (IQR: 0–181), and adverse events (Grade 3/4) were observed in 10.1% of patients versus 13.4% in the simulated control arm. The overall cost of AE avoided was estimated to€81,113, leading to an ICER of€864.Conclusion:The AMA programme was shown to be cost-effective compared to a simulated control arm with no intervention

Keywords: adverse events; chemotherapy; cost-effectiveness; healthcare quality; monitoring; oncologicnursing (search for similar items in EconPapers)
Date: 2022-11
Note: View the original document on HAL open archive server: https://hal.science/hal-03889400v1
References: Add references at CitEc
Citations:

Published in European Journal of Cancer Care, 2022, 31 (6), pp.e13709. ⟨10.1111/ecc.13709⟩

Downloads: (external link)
https://hal.science/hal-03889400v1/document (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-03889400

DOI: 10.1111/ecc.13709

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().